Rua Bioscience Limited — Director's Dealing 2026

Jan 19, 2026

==> picture [75 x 29] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

==> picture [511 x 511] intentionally omitted <==

----- Start of picture text ----- To NZX Limited; andName of listed issuer: Rua Bioscience Limited (Rua)Date this disclosure made: 20-Jan-26Date of last disclosure: 14-Nov-25Director or senior manager giving disclosureFull name(s): Teresa Farac-CiprianName of listed issuer: RuaName of related body corporate (if applicable): N/APosition held in listed issuer: DirectorSummary of acquisition or disposal of relevant interest (excluding specified derivatives)Class of affected quoted financial products: Ordinary sharesNature of the affected relevant interest(s): ShareholderFor that relevant interest-Number held in class before acquisition or disposal: 525,000Number held in class after acquisition or disposal: 875,000Current registered holder(s): N/A - new issue of sharesRegistered holder(s) once transfers are registered: Teresa Farac-CiprianSummary of acquisition or disposal of specified derivatives relevant interest (if applicable)Type of affected derivative: NAClass of underlying financial products: NADetails of affected derivative-The notional value of the derivative (if any) or the notional amount of underlyingfinancial products (if any): NAA statement as to whether the derivative is cash settled or physically settled: NAMaturity date of the derivative (if any): NAExpiry date of the derivative(if any): NAThe price specified in the terms of the derivative (if any): NAAny other details needed to understand how the amount of the consideration payableunder the derivative or the value of the derivative is affected by the value of theunderlying financial products: N/AFor that derivative,-Parties to the derivative: N/AIf the director or senior manager is not a party to the derivative, the nature of therelevant interest in the derivative: N/ADetails of transactions giving rise to acquisition or disposalTotal number of transactions to which notice relates: 1----- End of picture text -----

Details of transactions requiring disclosure-

==> picture [511 x 614] intentionally omitted <==

----- Start of picture text ----- Date of transaction: 18-Dec-25Nature of transaction: Issue of shares @ $0.025 per shareName of any other party or parties to the transaction (if known): Rua Bioscience LimitedThe consideration, expressed in New Zealand dollars, paid or received for the $8,750 relating to the issue of ordinary sharesacquisition or disposal. If the consideration was not in cash and cannot be readily byconverted into a cash value, describe the consideration:Number of financial products to which the transaction related: 350,000 sharesIf the issuer has a financial products trading policy that prohibits directors or seniormanagers from trading during any period without written clearance (a closed period)include the following details—Whether relevant interests were acquired or disposed of during a closed period: NoWhether prior written clearance was provided to allow the acquisition or disposal toproceed during the closed period: NADate of the prior written clearance (if any): NASummary of other relevant interests after acquisition or disposal:Class of quoted financial products: Ordinary SharesNature of relevant interest: Registered HolderFor that relevant interest,-Number held in class: 875,000 sharesCurrent registered holder(s): Teresa Farac-CiprianFor a derivative relevant interest,-Type of derivative: WarrantsDetails of derivative,-The notional value of the derivative (if any) or the notional amount of underlying301,925 warrants. At $0.015 warrant price is $4,528.88financial products (if any):No consideration is payable for the warrants. CashA statement as to whether the derivative is cash settled or physically settled: consideration of $0.015 per share is payable on exerciseof the warrantsMaturity date of the derivative (if any): 13/5/2028 and 5/6/2028Expiry date of the derivative (if any): 13/5/2028 and 5/6/2028The price's specified terms (if any): $0.015 per warrantAny other details needed to understand how the amount of the consideration payableunder the derivative or the value of the derivative is affected by the value of the N/Aunderlying financial products:For that derivative relevant interest,-Parties to the derivative:Teresa Farac-CiprianIf the director or senior manager is not a party to the derivative, the nature of the N/Arelevant interest in the derivative:CertificationI, certify that, to the best of my knowledge and belief, the information contained in thisdisclosure is correct and that I am duly authorised to make this disclosure by all personsfor whom it is made.Signature of person authorised to sign on behalf of director or officer:Date of signature: 20/01/2026Name and title of authorised person: Paul Naske, CEO----- End of picture text -----